CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intelligene Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intelligene Inc
Phone: +886 226558825p:+886 226558825 TAIPEI, 115  Taiwan Ticker: 78327832
Business Summary
Intelligene Inc is a Taiwan-based company primarily engaged in the development of innovative ribonucleic acid (RNA) gene therapy drugs. The Company is engaged in the research and development of innovative nucleic acid drugs based on small molecule interfering ribonucleic acid (siRNA) gene compilation technology for the treatment of all cases of pneumonia and influenza.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024-----

Industries
SIC Code Description
8731 Commercial physical and biological research

General Information
Number of Employees: 20 (As of 12/31/2024)
Outstanding Shares: 580,000,000 (As of 12/31/2024)
Stock Exchange: TPO
Fax Number: +886 226558890


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, May 8, 2025